Physician profile
Timothy Mark Stout
NPI 1316930688
$12,727.03
in general payments reported to CMS, 2019-2025
25 companies · $41.63 in 2025
The $41.63 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,913 · 2020: $587 · 2021: $713 · 2022: $797 · 2023: $4,506 · 2024: $4,170 · 2025: $41.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,350 · Travel and Lodging: $1,021 · Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,350.00 |
| Travel and Lodging | $1,020.68 |
| Food and Beverage | $346.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $7,350.00 | 2023-2024 | |
| Janssen Research & Development, LLC | $1,188.38 | 2024 | |
| Novartis Pharmaceuticals Corporation | $1,145.63 | 2019-2021 | |
| Biotissue Holdings INC. | $521.25 | 2019-2022 | |
| Allergan, INC. | $513.90 | 2019-2021 | |
| Sight Sciences, INC. | $498.39 | 2020-2022 | |
| Alcon Vision LLC | $227.53 | 2019-2023 | Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $213.28 | 2019-2021 | |
| Abbvie INC. | $204.24 | 2022 | |
| Eyepoint US, INC. | $166.62 | 2019-2021 | |
| Omeros Corporation | $135.30 | 2019 | |
| Mallinckrodt Hospital Products INC. | $95.78 | 2020-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $69.76 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $66.56 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $60.32 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $59.64 | 2022-2023 | Vyzulta, Prolensa |
| Mallinckrodt Enterprises LLC | $49.24 | 2019 | |
| Oyster Point Pharma, INC. | $41.17 | 2022 | |
| Rxsight INC | $24.03 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $19.85 | 2021 | |
| Genentech USA, INC. | $19.02 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $17.25 | 2024 | Xdemvy |
| Ani Pharmaceuticals, INC. | $16.08 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $12.52 | 2019 | |
| Ocular Therapeutix, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.